Despite these differences, transgenic expression of full-length utrophin can prevent muscle necrosis in sedentary mdx mice, thus making it a promising candidate for treating DMD patients, independent of the type or placement of the dystrophin mutation [44, 53]. This evidence concerns the gene UTRN and Duchenne muscular dystrophy.